Hemab Therapeutics Holdings key facts
as of Oct 2026- Developer of prophylactic therapeutics designed for bleeding and thrombosis disorders.
- Hemab Therapeutics Holdings is valued at approximately $386.9M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $355.1M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($157.0M) in Oct 2025.
- Notable investors include RA Capital Management, Novo Holdings, Sofinnova Partners, The Invus Group, BioInnovation Institute — 12 tracked in total.
- 5 institutional filers report fund marks on Hemab Therapeutics Holdings across 13 filings.
- Status: In IPO Registration.
Nothing comparable since the round — shown at its later-stage round, Oct 2025 ($386.9M post-money).
- ·The complete investor list: 12 names
- ·Watch Hemab Therapeutics Holdings: the Monday email on marks, rounds and moves
Institutional fund marks on Hemab Therapeutics Holdings
5 filers · latest Jul 20265 SEC-registered funds reported 13 fair-value marks on Hemab Therapeutics Holdings between May 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Hemab Therapeutics Holdings funding rounds
2 roundsWho backs Hemab Therapeutics Holdings
12+Hemab Therapeutics Holdings valuation
Hemab Therapeutics Holdings is valued at approximately $387 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Oct 2025, at a $387 million post-money valuation.
Recent activity
In the last 90 days, Hemab Therapeutics Holdings's record added 8 institutional fund marks (latest period Jul 2026).
How much has Hemab Therapeutics Holdings raised?
Hemab Therapeutics Holdings has raised $355 million across 2 recorded rounds since 2023. The largest was a $157 million Series C in Oct 2025.
Institutional holders and vehicles
5 SEC-registered funds reported 13 fair-value marks on Hemab Therapeutics Holdings between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Hemab Therapeutics Holdings investors
12 investors are on record for Hemab Therapeutics Holdings, including RA Capital Management, Novo Holdings, Sofinnova Partners and The Invus Group. The Series C in Oct 2025 drew 10 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: CORXEL Pharmaceuticals ($475 million), Diagonal Therapeutics ($459 million) and AgomAb ($416 million).
About Hemab Therapeutics Holdings
Developer of prophylactic therapeutics designed for bleeding and thrombosis disorders. The company's therapeutics accumulate, modulate, balance, and at times recruit endogenous clotting factors already present in the blood to the site of injury, enabling patients to form hemostatic plugs or clots to prevent life-threatening complications.
- Industry
- Drug Discovery
- Sector
- Financial Services
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 30
- Website
- hemab.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.